A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

Stopped Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

Conditions

• Chronic Hepatitis B

Interventions

• DRUG: TQA3605 tablets Placebo
• DRUG: TQA3605 Tablets
• DRUG: Entecavir dispersible tablets

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.